Literature DB >> 15616337

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.

Ben M Lomaestro1, G L Drusano.   

Abstract

A Monte Carlo simulation demonstrated that 1 g of meropenem (MEM) every 8 h (q8h) (3-h infusion) has a higher target attainment rate against Pseudomonas aeruginosa than either 500 mg of MEM q8h (3-h infusion) or 0.5 g of imipenem-cilastatin (I-C) q6h (1-h infusion). For other pathogens, 500 mg of MEM q8h was equivalent or superior to I-C.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15616337      PMCID： PMC538854          DOI： 10.1128/AAC.49.1.461-463.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Prevention of resistance: a goal for dose selection for antimicrobial agents.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

2.  Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions.

Authors:  A A Firsov; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

3.  Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Continuous infusion versus intermittent administration of meropenem in critically ill patients.

Authors:  F Thalhammer; F Traunmüller; I El Menyawi; M Frass; U M Hollenstein; G J Locker; B Stoiser; T Staudinger; R Thalhammer-Scherrer; H Burgmann
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

5.  Multiple-dose pharmacokinetics of imipenem-cilastatin.

Authors:  G L Drusano; H C Standiford; C Bustamante; A Forrest; G Rivera; J Leslie; B Tatem; D Delaportas; R R MacGregor; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection.

Authors:  C Domenig; F Traunmüller; S Kozek; W Wisser; W Klepetko; R Steininger; C Spiss; F Thalhammer
Journal:  Transplantation       Date:  2001-03-27       Impact factor: 4.939

Review 7.  The pharmacokinetics of meropenem.

Authors:  G L Drusano; M Hutchison
Journal:  Scand J Infect Dis Suppl       Date:  1995

Review 8.  The pharmacodynamics of beta-lactams.

Authors:  J D Turnidge
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079
  8 in total
  21 in total

1.  Does prolonged infusion allow lower daily dose of meropenem than bolus dosing?

Authors:  Eric Poulin; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

2.  Impact of sample size on the performance of multiple-model pharmacokinetic simulations.

Authors:  Vincent H Tam; Samer Kabbara; Rosa F Yeh; Robert H Leary
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

Review 3.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

4.  Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.

Authors:  G L Drusano; T P Lodise; D Melnick; W Liu; A Oliver; A Mena; B VanScoy; A Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.

Authors:  P Brian Smith; Michael Cohen-Wolkowiez; Lisa M Castro; Brenda Poindexter; Margarita Bidegain; Joern-Hendrik Weitkamp; Robert L Schelonka; Robert M Ward; Kelly Wade; Gloria Valencia; David Burchfield; Antonio Arrieta; Varsha Bhatt-Mehta; Michele Walsh; Anand Kantak; Maynard Rasmussen; Janice E Sullivan; Neil Finer; Beverly S Brozanski; Pablo Sanchez; John van den Anker; Jeffrey Blumer; Gregory L Kearns; Edmund V Capparelli; Ravinder Anand; Daniel K Benjamin
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

6.  Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.

Authors:  Idoia Bilbao-Meseguer; Alicia Rodríguez-Gascón; Helena Barrasa; Arantxazu Isla; María Ángeles Solinís
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

7.  Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Authors:  Thomas P Lodise; Rienk Pypstra; James B Kahn; Bindu P Murthy; Hui C Kimko; Karen Bush; Gary J Noel; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

8.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.

Authors:  Samir G Sakka; Anna K Glauner; Jürgen B Bulitta; Martina Kinzig-Schippers; Wolfgang Pfister; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 10.  Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Crit Care       Date:  2009-06-10       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.